Mavyret

Mavyret is a prescription antiviral medication used to treat chronic hepatitis C virus (HCV) infection. It combines two direct-acting antivirals, glecaprevir and pibrentasvir, in a fixed-dose tablet. The product is marketed by AbbVie. Mavyret is a pan-genotypic regimen intended for adults and certain pediatric patients with chronic HCV infection.

Indications and regimen

Mavyret is approved for treating chronic HCV infection across genotypes 1 through 6. The usual regimen is one tablet taken once daily with food for a set duration, commonly eight weeks for many patients. Some individuals, depending on genotype, prior treatment history, and liver condition, may require longer courses, such as 12 weeks, under clinician guidance. It is used in various treatment-naïve and treatment-experienced scenarios, including those with compensated cirrhosis in some cases.

Mechanism of action

Glecaprevir is an inhibitor of the HCV NS3/4A protease, which blocks viral polyprotein processing. Pibrentasvir inhibits the NS5A replication complex. By combining these agents, Mavyret targets two essential steps in the HCV life cycle, helping to prevent viral replication.

Administration and precautions

Mavyret is taken orally, once daily with food. It should be swallowed whole and taken consistently at about the same time each day. Doses should not be missed, and patients should follow their clinician’s instructions regarding duration. It is not generally recommended for patients with decompensated liver disease. Because the tablets interact with other medicines, including certain anticonvulsants and acid-suppressing drugs, patients should review all medications with a healthcare provider to assess potential drug interactions.

Efficacy and safety

Mavyret achieves high sustained virologic response rates in many patients. Common side effects include headache and fatigue, with nausea also reported. Serious liver-related adverse events are uncommon but possible, underscoring the need for clinical monitoring during treatment.

History

Mavyret was approved by the U.S. FDA in 2017 for adults and was subsequently expanded to include certain pediatric patients.